Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
about the author
ENDPOINTS
editor@endpointsnews.com
author articles
Intellia exits hemophilia B pact with Regeneron; Sangamo targets $24M raise
Last year
News Briefing
Meiji Seika Pharma to supply Japan with self-amplifying mRNA Covid-19 vaccine in fall/winter of 2024
Last year
Nikkei Biotechnology
Innate ends Ph1b in peripheral T cell lymphoma; Layoffs at NextCure
Last year
News Briefing
Madrigal's $600M offering; PureTech to return $100M to shareholders
Last year
News Briefing
Bluebird's $175M loan; Spyre reveals second private placement
Last year
News Briefing
OcuTerra’s diabetic retinopathy drug fails PhII; Better Therapeutics to shut down
Last year
News Briefing
Regulus raises $100M; Cancer company files to go public
Last year
News Briefing
Lexeo brings in $95M; FDA lifts hold on Nurix cancer trial
Last year
News Briefing
Ultimovacs' melanoma vaccine fails in PhII; Regenxbio’s $140M offering
Last year
News Briefing
BridgeBio's $250M offering; ViiV's PhI data for ultra-long-acting HIV treatment
Last year
News Briefing
Viking's $350M offering; Baker Brothers leads another PIPE
Last year
News Briefing
Denali’s $500M placement; Brain health startup raises $26M
Last year
News Briefing
Merrimack to dissolve after recording $225M milestone; Cogent's $225M placement
Last year
News Briefing
Kura’s stock jumps on PhIb readout; FDA lifts hold on INmune Bio program; Nanobiotix’s $20M milestone
Last year
News Briefing
Merck inks deal with Unnatural Products; CG Oncology’s upsized IPO; Locus gets $24M from BARDA
Last year
News Briefing
Doudna’s new venture; Aclaris CEO to step down; Tome’s $114M liver disorder deal with Genevant
Last year
News Briefing
#JPM24 quick hits: Ionis on partnership’s pros and cons; Novo Ventures has $600M to spend; Are small molecules ...
Last year
R&D
#JPM24 quick hits: Vibe check; Maze’s next turn; AI at pharma companies + more
Last year
Deals
AI
#JPM24 quick hits: A 'great year for M&A'; an optimistic Sarepta; Pfizer's CEO + more
Last year
Deals
R&D
Rhythm licenses obesity drug for $100M; Galapagos teams up with BridGene; Insilico’s new deal
Last year
News Briefing
All the new drugs approved in 2023: Alzheimer's and gene therapy cap a five-year high
Last year
FDA+
J&J’s new partnership with Elektrofi; Enyo raises €39M; Arrowhead's $450M offering
Last year
News Briefing
Theseus goes with Tang; Oncternal trial patient dies; LianBio sells drug rights to J&J
Last year
News Briefing
The 2023 winners and losers list: Who was up and who was down in biopharma
Last year
Pharma
First page
Previous page
10
11
12
13
14
15
16
Next page
Last page